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Primary melanoma generally evolves through three clinically and morphologically discernable tumor progression steps. Transformed
melanocytes first proliferate above the epidermal basement membrane, then invade the papillary dermis (the in situ and invasive radial
growth phases or melanoma), and subsequently develop the capacity to grow as a tumor (the vertical growth phase). Here, we address three
aspects of the invasive radial growth phase that provide the rationale for viewing it as the critical lesion for melanoma detection and therapy.
We determined the fraction of melanomas having this growth phase, tested its hypothesized incapacity to metastasize, and estimated its
longevity. The high prevalence of this step in tumor progression was demonstrated in a data base of 624 patients, where at least 87% of
melanomas exhibited a radial growth phase. The benignity of this lesion was evinced by the perfect metastasis-free survival of 161 patients
treated for pure radial growth-phase melanomas and followed for a median of 13.7 years. Its indolence was evident in an analysis of the ages
of 234 patients with superficial spreading melanomas without or with vertical growth phase: The cases with lesions having only radial growth
phase were 4.3 years younger than those additionally having vertical growth phase (Po0.05). These features of the invasive radial growth
phase of primary melanoma, first described by Wallace H. Clark, make it a pivotal lesion in the evolutionary biology of melanocytic neoplasia
and confirm its central place in public health programs to control melanoma mortality. J Invest Dermatol 100:342S-345S, 1993
Melanocytic neoplasia is a prototype of stepwise tumor progression.
Clinicopathologically identified lesions in its tumor progression pathway
include common acquired nevi, dysplastic nevi, primary melanoma, and
metastatic disease. Primary melanoma may progress through three
recognizable steps: in situ radial growth phase (RGP), invasive RGP,
and the vertical growth phase (VGP), or ‘‘tumorigenic melanoma’’ [1]. Of
these lesions, the invasive but non-tumorigenic RGP is of particular
importance as a candidate lesion for apprehension and therapy in
programs using public health education, screening, and surveillance to
blunt melanoma’s burgeoning mortality. To fulfill this role, the invasive
RGP should be a common step in tumor evolution with a high likelihood
of progression. Further, it should be readily recognizable; sufficiently
long-lived to allow detection and diagnosis; and curable with simple,
non-morbid, inexpensive surgery. Here, we address three of these issues:
the proportion of cutaneous melanomas exhibiting RGP, the apparent
incapacity of invasive RGP to metastasize, and the ‘‘longevity’’ of such
lesions. With respect to the first of these, in a data base of 624 patients
with melanoma with 697 primary lesions, 87% of the lesions had at least
a component of RGP. The second issue has been addressed in a previous
analysis of 149 patients with invasive RGP melanomas who were
followed for a minimum of 8 years with no metastases [2]; however,
these lesions were ‘‘thin,’’ and thin lesions may metastasize late [3]. The
present analysis confirms the benignity of invasive RGP melanoma: 161
patients with such lesions followed for at least 10 years had no
metastases. To address the third issue, we examined the ages of patients
with pure, invasive RGP melanomas and of those with primaries having
both RGP and VGP. In an analysis of patients with superficial spreading
melanomas, we found that those having only invasive RGP had a mean
age 4.3 years younger than that of patients with primaries having both
RGP and VGP (Po0.05). For patients with lentigo maligna melanomas
without and with VGP, the mean ages were 64.3 and 67.9 years,
respectively. As a surrogate for a direct measure of the duration of the
invasive RGP, the differences of several years in the ages of these patients
is evidence that the invasive RGP is indolent.
MATERIALS AND METHODS
Histology of the RGP and VGP of Melanoma The histologic characteristics of the
growth phases of primary melanoma have been described fully and illustrated
elsewhere [2]. Briefly, RGP melanoma is malignant melanoma that is either in situ
(confined to the epidermis above an intact basement membrane—not the subject of
this report) or invasive but without markers for proliferation in the dermis (non-
tumorigenic). If there is evidence for dermal proliferation, the tumor is said to have
entered the VGP (tumorigenic melanoma). Primary criteria for the recognition of
tumorigenic proliferation in the dermis include the presence of one or more clusters
of cells in the dermis that are larger than those in the epidermis and/or the presence
of any mitoses in lesional cells in the dermis. VGP is usually also associated with
evidence of expansile growth and/or growth preference compared with surround-
ing cells of the RGP, with changes in the cellular phenotype that are consistent with
clonal evolution, and with a less prominent lymphocytic response. Most tumors
that exceed 1mm in thickness fill and expand the papillary dermis (level III), or
invade the reticular dermis (level IV) are in the VGP.
Data Base Construction of a computerized data base of melanoma cases presenting
to the University of Pennsylvania Pigmented Lesion Study Group has been
described in detail elsewhere [2]. At the time of the present study, the data base
contained information on 624 invasive melanoma cases presenting between
September 1, 1972 and December 31, 1979. Most patients were seen prior to
definitive therapy of their primary lesion, and 96% were seen within 90 days of
diagnosis. Pathology review of the primary lesions generated 65 attributes,
including histogenetic type, thickness, and growth phase(s). This was done without
knowledge of outcome and was independently conducted by two pathologists
(David E. Elder and Wallace H. Clark) 7–8 years following definitive therapy.
Differences between the pathologists’ opinions were resolved by joint review and
consensus. Doubtful cases with respect to the presence of VGP were placed in the
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VGP category. Follow-up data were collected through visits to the Pigmented
Lesion Study Group, by mail questionnaire, or by telephone interviews with
patients and their local physicians.
Analyses For the analysis of the proportion of cases with RGP, the entire data set of
624 cases having 697 primary melanomas (all cutaneous but for two mucosal) was
used. To analyze the distant-metastasis—free survival of invasive RGP cases and to
compare it with a group of ‘‘thin’’ VGP cases, 251 cases with primaries either
having only RGP or exhibiting VGP with a tumor thickness of less than 0.76mm
were considered. Additional patients were excluded for the following reasons:
American Joint Commission on Cancer (AJCC) stage III (regional lymph nodes
involved) at presentation (two cases, one with thin VGP and one classified as ‘‘VGP
absent’’ by virtue of near total regression of the primary, although regression was
not itself a criterion for exclusion); inadequate or incomplete surgical excision of
the primary (eight cases); lack of prospective follow-up (five cases); and occurrence
of a second primary of higher risk after 1979 (one case). These exclusions resulted
in a study sample of 235 cases, of which 161 were considered ‘‘RGP only,’’ and 74
were ‘‘thin VGP.’’ The RGP-only lesions had a median thickness of 0.35mm (range
0.07–1.47), whereas the thin VGP lesions had a median thickness of 0.60mm
(range 0.27–0.75). Survival distributions were estimated using the Kaplan-Meier
method [4], and the Mantel-Cox log rank test [5] was used for statistical comparison
of the distributions.
To estimate the longevity of invasive RGP melanomas, we hypothesized that, as
a group, patients with RGP-only melanomas would be younger than those who had
melanomas that had evolved through the RGP to develop VGP, that is, patients who
had both growth phases histologically evident. For this analysis we considered only
the 468 cases with superficial spreading or lentigo maligna melanomas, and these
histogenetic types were analyzed separately because of their different age-specific
incidences [6]. Cases were prospectively excluded that had attributes which might
themselves be associated with age. Thus, cases were excluded that had primaries
with a dysplastic or congenital precursor (142 cases) or a history of melanoma in a
first-degree relative (13 cases) [7]. Additional exclusions were for metastatic disease
at the time of presentation (12 cases), no prospective follow-up (eight cases), an
uncertain or missing classification of the presence of VGP (19 cases), or no
measurement of tumor thickness (one case). The final study sample was 273 cases,
of which 234 had superficial spreading melanomas, and 39 had lentigo maligna
melanomas. Seventy-five of the former (32%) were classified as RGP only, as were
20 of the lentigo maligna melanomas (51%). The mean ages of patients with RGP-
only and VGP melanomas for each of the two histogenetic types of melanomas
were compared by the Mann-Whitney test. For patients with superficial spreading
melanomas, we also compared the ages of patients with RGP melanomas with the
ages of patients with VGP melanomas by thickness group. This was also done for
female and male patients separately. The equality of means was tested by analysis
of variance. Duncan’s multiple-comparison procedure was used to compute
pairwise comparisons of the group means, with a¼ 0.05. In patients with
superficial spreading melanoma, the age distributions by decade without and with
VGP were compared by the likelihood-ratio chi-square test. There were too few
cases of lentigo maligna melanoma to perform the two latter analyses.
RESULTS
Proportion of Lesions with RGP The 624 patients who comprise the data
base have had 697 cutaneous melanomas, 604 (87%) of which have had
at least a component of RGP. Forty-five (7%) of these cases had two or
more primaries (simultaneous or subsequent). Of these 73 lesions, 69
(95%) had at least an element of RGP.
Survival and Freedom from Metastasis of Patients with RGP and VGP
Melanomas Of 235 cases in the study sample, surviving patients have
been followed for a minimum of 10 years, with median follow-up times
of 13.7 years for the 161 RGP-only cases and 13.2 years for the 74 thin
VGP cases. Neither regional nor distant metastases due to melanoma
occurred in the RGP-only cases (Fig 1). There were 17 RGP cases with
less than 10 years follow-up, all without evidence of melanoma at last
contact (one patient died of unknown causes; 12 died of other causes;
and four were lost to follow-up). Of the 144 patients with RGP
melanomas with 10 or more years of follow-up, 129 remain alive and
free of metastatic melanoma (one with a 37-cm lentigo maligna
melanoma treated by narrow excision had a local recurrence of RGP
melanoma treated with re-excision at 7.3 years from initial surgery and
remains disease free at an additional 6þ years); 10 died of other causes,
and five were lost to follow-up. Forty-two patients have been followed for
15 or more years, 29% of those who entered the 10-year interval.
The patients with thin VGP melanomas had a significantly different
10-year survival experience of 88% (Po0.0001); there were eight deaths
from metatstatic melanoma prior to 10 years (Fig 1). In addition, two
developed AJCC stage III disease, one at 3.8 years and the other at 6.8
years from primary surgery (both are disease free at 11.3 and 6.3 years,
respectively, from regional node dissections). Nine additional patients
had less than 10 years of follow-up: seven died of other causes, and two
were lost to follow-up. Of the 57 patients with thin VGP melanomas with
10 years of follow-up, 55 remain alive and free of melanoma, one died of
other causes, and one was lost to follow-up. Sixteen patients have been
in follow-up for 15 or more years, 28% of those entering the 10-year
interval (the same proportion as in the RGP-only cases).
‘‘Longevity’’ of RGP Melanoma To estimate the duration of the invasive
RGP of melanoma both for patients with superficial spreading
melanomas and lentigo maligna melanomas, we compared the ages of
those with pure RGP melanomas to those of patients with both RGP and
VGP melanomas. As shown in Table I, patients with superficial spreading
melanomas with only RGP (‘‘VGP absent’’) were on average 4.3 years
younger than patients with both growth phases (Po0.05). Patients with
lentigo maligna melanomas with VGP absent were 3.6 years younger on
average than those with VGP, but this difference was not statistically
significant.
Among the patients with superficial spreading melanomas, we also
compared the ages of the 75 patients with RGP only (VGP absent) with
the ages of the 159 patients with both RGP and VGP melanomas in
groups of increasing thickness. As seen in Table II, the five sets of tumors
(RGP through the thickest of the VGP lesions) had about a twofold
Figure 1. Cumulative distant metastasis-free survival curves for 74 ‘‘thin
VGP’’ cases (A) and 161 ‘‘RGP-only’’ cases (B). In parentheses below the
curves at 120 and 180 months are the number of cases at risk at these points.
Survival is significantly different (Po0.0001).
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thickness increment from one set to the next. Paralleling this was an
increase in ages of the patients such that the RGP-only group (VGP
absent) and the thinnest of the VGP groups were significantly younger than
the thickest VGP groups.
Collapsing the two thinnest VGP groups into a single one (o1.70mm)
with a median thickness of 0.98mm yields a mean age of 44.8 years. This
grouping makes only the age of the pure-RGP group significantly different
from that of the VGP groups. Subdividing the cases by gender resulted in
no substantial differences from the data presented in Table II (not shown).
Finally, we examined the age distributions by decade of the cases
with superficial spreading melanoma with RGP only and with both
growth phases (VGP). As shown in Fig 2, this analysis demonstrates a
younger ‘‘peak’’ of RGP-only cases compared with the VGP cases. To test
for statistical significance and owing to the small number of occurrences
of disease in the second and eighth decades, the cells of the second and
third decade as well as those of the seventh and eighth were combined to
increase the minimum expected cell frequency. The distributions of the
two classifications of cases were significantly different (Po0.05).
DISCUSSION
Clark et al suggested over 15 years ago that primary melanomas generally
evolve in sequential steps from disease above the basement membrane to
invasive disease with ‘‘little or no potential for metastasis’’ [6]. This RGP
was described as ‘‘a lesion composed of melanoma cells within the
epidermis and papillary dermisy [with a] lack of biologic potential for
metastasisy in spite of invasion of the papillary dermis for
some years’’ [6]. The RGP is often followed by a ‘‘qualitatively different
growth patterny the vertical growth phase, [which] may, in turn, give
rise to cell populations commonly associated with metastatic disease’’
[6].
The present study sought to test three hypotheses inherent in these
statements: 1) that primary melanomas usually have an identifiable,
biologically early, invasive phase; 2) that this is a step in tumor
progression in which competence for metastasis has not been achieved;
and 3) that this lesion step is of sufficient duration to allow detection,
diagnosis, and therapy. The data presented here with respect to the RGP
of melanoma support all three postulates.
That 87% of the melanomas in the data base had only RGP or had an
element of RGP demonstrates that this phase of growth is a very common
step in the tumor progression pathway of melanoma. In fact, this
proportion is probably an underestimate because the RGP of melanomas
with an associated VGP may be obliterated with time and continuing
growth of the VGP. That this is the case is suggested by the higher fraction
of second or greater lesions with RGP in the cases with multiple
melanomas (95%). These lesions are presumably found earlier in their
evolution because of heightened patient and physician awareness, as
indicated in studies of familial melanoma [8].
That pure, invasive RGP melanoma cases had metastasis-free survival
for well beyond 10 years is a powerful argument for the incapacity of the
RGP to accomplish the multiple tasks beyond invasion (or descent)
through the basement membrane necessary to establish metastatic
disease. This argument is bolstered by the experience of VGP cases
followed long term. The flat metastasis-free survival curve of ‘‘thin VGP’’
cases beyond 10 years (see Fig 1) and the event-free survival of the same
proportion of cases as had RGP from 10 to beyond 15 years indicate that
a comparably ‘‘thin’’ group of biologically more advanced cases had
exhausted its metastatic potential. Thus, it is unlikely that the ‘‘perfect’’
metastasis-free survival of RGP cases is an artifact of inadequate follow-
up. This ‘‘qualitatively difFerent’’ character of the RGP in comparison to
the VGP is echoed in a number of in vitro and in situ characteristics of
cells and tissues representing the two growth phases [9,10].
The issue of the longevity of the RGP of melanoma prior to the onset
of VGP is not one that can be addressed rigorously. The question itself is
theoretically unanswerable because it is impossible to know fully the
histology of a lesion and its natural history (the pathologist’s equivalent of
Heisenberg’s uncertainty principle). Further, it is likely that the longevity
of the RGP is highly variable from case to case. Nevertheless, it is
important to the rationale of intervention strategies that there be some
Table I. Ages of Patients with Superficial Spreading





of Cases VGPc Mean Median Range
SSMa 75 Absent 43.1d 42.2 17.2–74.2
159 Present 47.4d 49.2 19.0–78.2
LMMb 20 Absent 64.3e 64.6 45.3–88.8






Table II. Ages of Patients with Superficial Spreading









Thickness (mm) Mean Median
Absent Not applicable 75 0.36 43.1a 42.2
Present o0.76 30 0.62 41.3a 36.7
0.76–1.69 69 1.15 46.7 47.1
1.70–3.60 45 2.14 49.5 50.8
43.6 15 5.18 56.2 60.7
aSignificantly different from other mean ages (Po0.05) but not one
another.
Figure 2. The age distributions by decade of 75 ‘‘RGP-only’’ cases (solid bars)
and 159 ‘‘VGP’’ cases (hatched bars) of superficial spreading melanoma.
The distributions are significantly different (Po0.05).
344S GUERRY ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
assurance that the RGP is not ephemeral. This assurance comes from
three sources, as initially articulated by Clark et al [6]. First, it is common
for patients to describe a long flat phase of growth prior to the evolution
of focal elevation in a melanoma with RGP and VGP. Second, we and
others have occasionally photographically captured a flat lesion that
grew only slowly and was ultimately biopsied to demonstrate RGP
melanoma throughout or that demonstrated VGP as a nodule of recent
onset in a flat RGP lesion of long duration [11].
The third approach, and that taken here, is to compare the ages of
patients with RGP melanomas with those of patients with both RGP and
VGP melanomas. In cases of superficial spreading melanoma and using
level II as a surrogate for RGP and levels IV plus V as a surrogate for VGP,
Clark et al reported median ages of 40 and 52 years, respectively, and
suggested that the RGP ‘‘may exist for about 12 years’’ [6]. In a
comparable recent study, 307 patients (mean age 43.9 years) with thin
superficial spreading melanomas (tumor thickness S0.76mm) were
insignificantly younger than 284 patients with lesions 0.76-1.50mm
thick (mean age 46.9 years) but were significantly younger than 204
patients with lesions 1.51–3.00mm thick (mean age 50.1 years) [12]. In
another study of superficial spreading melanomas, Sagebiel et al
compared the mean ages of 95 patients with in Htu melanomas (44.4
years) with those of ‘‘early invasive’’ melanomas (46.9 years) [13].
In the present analysis, we attempted to deal with confounding by
certain age-associated variables by separately studying patients with
lentigo maligna melanomas and those with superficial spreading
melanomas. Among the latter, we excluded patients with histologic
evidence of melanocytic dysplasia at the primary site because of the
younger age of patients with melanomas with dysplastic nevi [7] or a
family history of melanoma [14]. Without formal analysis of the age
distribution of patients with congenital precursors, we also prospec-tively
excluded these cases (3.3% of superficial spreading melanomas in our
data base are associated histologically with a nevus with ‘‘congenital-
type’’ features, and the median age of patients with these lesions is 44
years).
Because the apparent differences in ages of patients with and without
VGP melanomas are also consistent with difFerent behavioral character-
istics of age cohorts (e.g., earlier diagnosis in younger patients), these
data cannot be unambiguously interpreted. Indeed, all analyses of RGP
longevity, including that presented here, are problematic. Nevertheless,
taken together they provide evidence that the RGP of melanoma has a
duration measured in years.
The present study is but one example of the conceptual power of
Clark’s application of the principles of tumor progression to a specific,
human neoplastic system. The RGP of melanoma is a critical lesion in
understanding the biology of melanoma and in the effort to control
mortality from the melanoma epidemic. It also reminds us of the utility of
the tumor progression paradigm as applied by Clark to the general
problem of neoplasia [15]. Invasive disease without competence for
metastasis, whether in mammary, colonic, or other neoplastic systems, is
a critical lesion in tumor biology (where it holds the promise for
understanding the qualitative difference between invasive neoplasms
without and with metastatic competence) and in the arena of public
health (where its diagnosis and therapy hold the key to diminishing
mortality from malignant disease).
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